ArticleCancers2026
Lymphatic Mapping to the Inguinal Region in Patients with Lower Extremity Melanoma Undergoing Radical Inguinal Lymph Node Dissection: A Retrospective Cohort Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND/
objectivesThe anatomical distribution of inguinal lymph node (ILN) metastases may inform research on the extent of therapeutic dissection for lower-limb melanoma.
methodsFifty-eight patients undergoing radical inguinal lymph node dissection (rILND) were retrospectively evaluated using five anatomical zones. Zone-specific node counts were reaggregated, and exploratory binary logistic regression assessed multiple-zone involvement.
resultsThe cohort included 48 clinically node-positive and 10 sentinel lymph node biopsy (SLNB)-positive patients. Among 816 mapped ILNs, 149 were positive. Zone I contained 102/149 positive nodes (68.5%); within-zone positivity was 102/303 (33.7%) in zone I, 27/243 (11.1%) in zone II, 13/190 (6.8%) in zone III, 3/39 (7.7%) in zone IV, and 4/41 (9.8%) in zone V. Five patients had no positive mapped ILNs. Zone I contained the only positive node in 19/20 patients (95.0%) and was the sole involved zone in 32/33 patients with single-zone involvement (97.0%). Twenty patients had multiple-zone involvement. In a two-variable complete-case model (50 patients; 18 events), ≥3 positive ILNs remained associated with multiple-zone involvement (adjusted odds ratio, 34.80; 95% confidence interval, 5.88-206.08), whereas extranodal extension did not.
conclusionsThis small, selected cohort provides preliminary pathological evidence of preferential inferior-zone involvement. It does not establish sequential spread or the oncological safety of reduced rILND. External and prospective validation are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.